Johnson & Johnson: Breast Neoplasms trials

The registry lists 14 Breast Neoplasms studies with Johnson & Johnson as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 3Phase 2 5Phase 3 5Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast CancerRecruitingNCT07524855Phase 1
• A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole TherapyCompletedNCT01381874Phase 2Results posted
• Coated VICRYL* Plus Suture Compared to Chinese Silk in Scheduled Breast Cancer SurgeryCompletedNCT00768222Phase 4Results posted
• A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard ChemotherapyCompletedNCT00338286Phase 3Results posted
• A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast CancerCompletedNCT00091442Phase 3Results posted
• ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)Active, not recruitingNCT04829604Phase 2
• A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)CompletedNCT03255070Phase 1
• A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian CancerCompletedNCT01815294Phase 1
• GeneSearch™ Breast Lymph Node (BLN) Assay China Registration StudyTerminatedNCT00869674Phase 3
• An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast CancerCompletedNCT00580112Phase 2
• A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving ChemotherapyCompletedNCT00211133Phase 3
• To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and OlderTerminatedNCT00082095Phase 3
• A Study of ET-743 (Trabectedin) in Patients With Advanced Breast CancerCompletedNCT00050427Phase 2
• Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast CancerCompletedNCT00050141Phase 2